Top

Drugs

Published in:

01-03-2003 | Adis Drug Profile

Imatinib Mesylate

In the Treatment of Gastrointestinal Stromal Tumours

Authors: Katherine F. Croom, Caroline M. Perry

Published in: Drugs | Issue 5/2003

Abstract

▴ Imatinib mesylate (imatinib) is an orally administered competitive inhibitor of the tyrosine kinases associated with the KIT protein (stem cell factor receptor), ABL protein and platelet-derived growth factor receptors. The KIT tyrosine kinase is abnormally expressed in gastrointestinal stromal tumour (GIST), a rare neoplasm for which there has been no effective systemic therapy.
▴ In a randomised, nonblind, multicentre study that evaluated imatinib 400 or 600mg once daily in 147 patients with advanced GIST, confirmed partial responses were achieved in 54% of patients overall (median duration of follow-up was 288 days). Stable disease was experienced by 28% of patients and the estimated 1-year survival rate was 88%.
▴ Similar response rates were reported in a smaller, dose-escalation study, in which objective tumour response was a secondary endpoint.
▴ Although nearly all patients with GIST treated with imatinib experienced adverse events, most events were mild or moderate in nature. Severe or serious adverse events occurred in 21 % of patients in the larger study, and included gastrointestinal or tumour haemorrhage.

Griffin J. The biology of signal transduction inhibition: basic science to novel therapies. Semin Oncol 2001 Oct; 28 (5 Suppl 17): 3–8PubMedCrossRef

Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105(1): 3–7PubMedCrossRef

Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997; 1333: F217–48PubMed

Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 2001; 61(12): 1765–74; discussion 1775-6PubMedCrossRef

Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295(1): 139–45PubMed

Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996 May; 2: 561–6PubMedCrossRef

Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002 Feb 28; 346(9): 683–93PubMedCrossRef

Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30(10): 1213–20PubMedCrossRef

Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2001 Dec; 2(6): 485–91PubMedCrossRef

10.

Berman J, O’Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001 Jun; 32(6): 578–82PubMedCrossRef

11.

DeMatteo RP, Lewis J, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231(1): 51–8PubMedCrossRef

12.

McGrath PC, Neifeld JP, Lawrence Jr. W, et al. Gastrointestinal Sarcomas: analysis of prognostic factors. Ann Surg 1987; 206: 706–10PubMedCrossRef

13.

Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20(18): 3898–905PubMedCrossRef

14.

Heinrich MC, Corless CL, Blanke C, et al. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology 2002 May 1; 21: 2 (plus oral presentation)

15.

Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001 Apr 5; 344(14): 1052–6PubMedCrossRef

16.

Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96(3): 925–32PubMed

17.

Glivec® GIST clinical monograph. Basel, Switzerland: Novartis Pharma AG, 2002

18.

Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938–42PubMedCrossRef

19.

Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001 Aug 16; 20(36): 5054–8PubMedCrossRef

20.

Krystall GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000 Aug; 6: 3319–26

21.

Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminoprimidine derivative. Cancer Res 1996; 56: 100–4PubMed

22.

Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997 Dec 15; 90: 4947–52PubMed

23.

Attoub S, Rivat C, Rodrigues S, et al. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 2002 Sep 1; 62(17): 4879–83PubMed

24.

le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999 Jan 20; 91(2): 163–8PubMedCrossRef

25.

Shimizu A, O’Brien KP, Sjöblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type I α 1/platelet-derived growth factor (PDGF) β-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999; 59: 3719–23PubMed

26.

Sjöblom T, Shimizu A, O’Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist ST1571 through induction of apoptosis. Cancer Res 2001; 61: 5778–83PubMed

27.

Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000; 60: 5143–50PubMed

28.

Uehara H, Kim SJ, Karashima T, et al. Blockade of PDGF-R signaling by STI571 inhibits angiogenesis and growth of human prostate cancer cells in the bone of nude mice [abstract]. 92nd Ann Meet Am Assoc Cancer Res 2001 Mar; 42: 407

29.

Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002 Aug 15; 347(7): 472–80PubMedCrossRef

30.

Committee for Proprietary Medicinal Products. European public assessment report on Glivec (Revision 1): scientific discussion. London, UK: European Agency for the Evaluation of Medicinal Products, 2002; CPMP/2418/01

31.

Gleevec™ (imatinib mesylate) capsules prescribing information. USA: Novartis, 2002

32.

Reckmann AH, Fischer T, Peng B, et al. Effect of food on STI571 Glivec pharmacokinetics and bioavailability [abstract]. 37th Annual Meeting of the American Society of Clinical Oncology 2001 May 12; 20 (Part 1): 307

33.

Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1031–7PubMedCrossRef

34.

Summary of product characteristics: Glivec 100mg capsules. Horsham, United Kingdom: Novartis Europharm Limited, 2002

35.

Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002 Oct; 8(10): 3034–8PubMed

36.

vanOosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumours: a report of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2002; 38 Suppl. 5: S83–7PubMedCrossRef

37.

van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001 Oct 27; 358(9291): 1421–3PubMedCrossRef

38.

Novartis Oncology. Glivec® First successful systemic treatment for GIST. 2002; Symposium highlights. (Data on file)

39.

Blanke CD, von Mehren M, Joensuu H, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors expressing C-KIT [abstract]. 37th Annual Meeting of the American Society of Clinical Oncology 2001 May 1; 20: 1 (plus oral presentation)

40.

Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239–53PubMedCrossRef

41.

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(3): 205–16PubMedCrossRef

42.

von Mehren M, Blanke C, Joensuu H, et al. High incidence of durable responses induced by imatinib mesylate (Gleevec™) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs) [abstract]. Proc Am Soc Clin Oncol 2001; 20: 1A

43.

Oken MM, Creech RH, Douglass CT, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–55PubMedCrossRef

44.

Bauer S, Hagen V, Pielken HJ, et al. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. Anticancer Drugs 2002 Sep; 13(8): 847–9PubMedCrossRef

45.

National Cancer Institute. Clinical Trials [online]. Available from URL: http://cancer.gov/clinical_trials [Accessed 2003 Jan 15]

Title: Imatinib Mesylate
In the Treatment of Gastrointestinal Stromal Tumours
Authors: Katherine F. Croom
Caroline M. Perry
Publication date: 01-03-2003
Publisher: Springer International Publishing
Published in: Drugs / Issue 5/2003
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200363050-00005

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Imatinib Mesylate

In the Treatment of Gastrointestinal Stromal Tumours

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2003

Clinical Potential of Sodium-Calcium Exchanger Inhibitors as Antiarrhythmic Agents

Diagnosis and Treatment of Patients with Pouchitis

Progestogens with Antiandrogenic Properties

Imatinib Mesylate

Imatinib Mesylate

Intramuscular Preparations of Antipsychotics